WASHINGTON – The Natural Products Association today issued the following statement on the President’s FY 2023 Budget Request to Congress regarding the section on the U.S. Food and Drug Administration (FDA):
“FDA’s proposal to include mandatory product listing in their FY23 budget request is a non-starter. Year after year, FDA receives more funding, including a $2 million increase in FY22. Yet, despite these increases, FDA consistently does less with more. Mandatory product listing is pre-market approval disguised as transparency and would only add to the bureaucratic nightmare the industry is experiencing with NAC and CBD,” said Daniel Fabricant, President and CEO of NPA.